A phase II proof of concept trial of cenicriviroc in combination with evogliptin in non-alcoholic steatohepatitis

Trial Profile

A phase II proof of concept trial of cenicriviroc in combination with evogliptin in non-alcoholic steatohepatitis

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Cenicriviroc (Primary) ; Evogliptin (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 This trial was planned by Tobira Therapeutics which has now acquired by Allergan according to a Allergan media release.
    • 01 Sep 2016 New trial record
    • 09 Aug 2016 According to a Tobira Therapeutics media release, this trial is expected to initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top